Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 17/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762292 | 0.87 | BDKRB1 (0.64) | BDKRB1 | |
| SCHEMBL6766954 | 0.85 | BDKRB1 (0.51) | BDKRB1RECQL | |
| SCHEMBL5393526 | 0.78 | BDKRB1 (0.53) | BDKRB1 | |
| SCHEMBL12943372 | 0.78 | BDKRB1 (0.58) | BDKRB1 | |
| SCHEMBL5951014 | 0.77 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL5950480 | 0.77 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL5951011 | 0.77 | BDKRB1 (0.55) | BDKRB1 | |
| Trifluoroacetic Acid SCHEMBL5381981 | 0.74 | BDKRB1 (0.49) | BDKRB1 | |
| SCHEMBL6761747 | 0.73 | RAB9A (0.48) | KDM4ERAB9A | |
| SCHEMBL6766732 | 0.73 | BDKRB1 (0.48) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885KDM4E 3858/4885RECQL 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.